Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Complete Title: ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study

Trial Phase: III

Investigator: Julie Park, MD

This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treatment until it progresses. In this case, observation may be sufficient. Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and what the best treatment is. Response and biology-based risk factor-guided therapy may be effective in treating patients with non-high risk neuroblastoma and may help to avoid some of the risks and side effects related to standard treatment.

Keywords:

Pediatric Cancers, Miscellaneous
Neuroblastoma
Solid Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms
Neuroectodermal Tumors
Neoplasms, Glandular and Epithelial
Ganglioneuroblastoma
Neoplasms, Neuroepithelial

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.